Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Medigene AG

< Previous 1 2 Next >
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024
From Medigene AG
Via GlobeNewswire
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Investor Conferences
From Medigene AG
Via GlobeNewswire
Medigene AG reports Financial Results and Business Update for Q3 2024
From Medigene AG
Via GlobeNewswire
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
From Medigene AG
Via GlobeNewswire
Medigene will Present at ASGCT 2024 and Host R&D Event
From Medigene AG
Via GlobeNewswire
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
From Medigene AG
Via GlobeNewswire
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
From Medigene AG
Via GlobeNewswire
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
From Medigene AG
Via GlobeNewswire
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
From Medigene AG
Via GlobeNewswire
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Investor Conferences
From Medigene AG
Via GlobeNewswire
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
From Medigene AG
Via GlobeNewswire
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
From Medigene AG
Via GlobeNewswire
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
From Medigene AG
Via GlobeNewswire
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
From Medigene AG
Via GlobeNewswire
Medigene to Present at ESMO Congress 2024
From Medigene AG
Via GlobeNewswire
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
From Medigene AG
Via GlobeNewswire
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
From Medigene AG
Via GlobeNewswire
Medigene Reports Results of Annual General Meeting
From Medigene AG
Via GlobeNewswire
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
From Medigene AG
Via GlobeNewswire
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
From Medigene AG
Via GlobeNewswire
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
From Medigene AG
Via GlobeNewswire
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
From Medigene AG
Via GlobeNewswire
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
From Medigene AG
Via GlobeNewswire
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Conferences
From Medigene AG
Via GlobeNewswire
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
From Medigene AG
Via GlobeNewswire
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
From Medigene AG
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.